BACKGROUND: Markers of systemic inflammation, including blood leukocyte count, are associated with increased cardiovascular risk, but the mechanisms underlying this association are unclear. Leukocytes may promote platelet reactivity and thrombus formation, providing a basis for increased risk, but a relation between leukocyte count and platelet function has not been studied. METHODS: We evaluated the relation of blood leukocyte count, C-reactive protein (CRP), and interleukin-6 (IL-6) to platelet aggregation to collagen, ADP and arachidonic acid, and to urinary excretion of 11-dehydro thromboxane B2. Studies were conducted in 1600 individuals (45.0+/-12.9 years, 42.7% male) at risk for coronary artery disease (CAD) before and after low dose aspirin. RESULTS: At baseline, platelet reactivity increased with increasing quartile of leukocyte count (median counts for each quartile were normal) for all measures of platelet function (P<0.0001). These relations were unchanged by aspirin. The relation between leukocyte count and each measure of platelet reactivity remained significant (P<0.05) after multivariable adjustment for CRP, IL-6, cardiac risk factors, hematologic variables, and platelet thromboxane production. CRP and IL-6 were independently associated with few measures of platelet reactivity. CONCLUSIONS: Increasing quartile of leukocyte count, even within the normal range, is associated with increasing platelet reactivity in individuals at risk for CAD. This relationship is not altered by aspirin and is independent of inflammatory markers and platelet thromboxane production. Additional studies are needed to determine the mechanism(s) for this association and therapies to reduce cardiovascular risk in patients with elevated leukocyte counts.
BACKGROUND: Markers of systemic inflammation, including blood leukocyte count, are associated with increased cardiovascular risk, but the mechanisms underlying this association are unclear. Leukocytes may promote platelet reactivity and thrombus formation, providing a basis for increased risk, but a relation between leukocyte count and platelet function has not been studied. METHODS: We evaluated the relation of blood leukocyte count, C-reactive protein (CRP), and interleukin-6 (IL-6) to platelet aggregation to collagen, ADP and arachidonic acid, and to urinary excretion of 11-dehydro thromboxane B2. Studies were conducted in 1600 individuals (45.0+/-12.9 years, 42.7% male) at risk for coronary artery disease (CAD) before and after low dose aspirin. RESULTS: At baseline, platelet reactivity increased with increasing quartile of leukocyte count (median counts for each quartile were normal) for all measures of platelet function (P<0.0001). These relations were unchanged by aspirin. The relation between leukocyte count and each measure of platelet reactivity remained significant (P<0.05) after multivariable adjustment for CRP, IL-6, cardiac risk factors, hematologic variables, and platelet thromboxane production. CRP and IL-6 were independently associated with few measures of platelet reactivity. CONCLUSIONS: Increasing quartile of leukocyte count, even within the normal range, is associated with increasing platelet reactivity in individuals at risk for CAD. This relationship is not altered by aspirin and is independent of inflammatory markers and platelet thromboxane production. Additional studies are needed to determine the mechanism(s) for this association and therapies to reduce cardiovascular risk in patients with elevated leukocyte counts.
Authors: Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert Journal: Circulation Date: 2002-07-16 Impact factor: 29.690
Authors: Michael N Zairis; Evdokia N Adamopoulou; Stavros J Manousakis; Anastassios G Lyras; George P Bibis; Olga S Ampartzidou; Charalambos S Apostolatos; Filippos A Anastassiadis; John J Hatzisavvas; Spyros K Argyrakis; Stefanos G Foussas Journal: Atherosclerosis Date: 2006-09-08 Impact factor: 5.162
Authors: John W Eikelboom; Jack Hirsh; Jeffrey I Weitz; Marilyn Johnston; Qilong Yi; Salim Yusuf Journal: Circulation Date: 2002-04-09 Impact factor: 29.690
Authors: Nauder Faraday; Lisa R Yanek; Rasika Mathias; J Enrique Herrera-Galeano; Dhananjay Vaidya; Taryn F Moy; M Daniele Fallin; Alexander F Wilson; Paul F Bray; Lewis C Becker; Diane M Becker Journal: Circulation Date: 2007-04-30 Impact factor: 29.690
Authors: Rehan Qayyum; Diane M Becker; Lisa R Yanek; Nauder Faraday; Dhananjay Vaidya; Rasika Mathias; Brian G Kral; Lewis C Becker Journal: Clin Transl Sci Date: 2014-07-25 Impact factor: 4.689
Authors: John D Eicher; Ming-Huei Chen; Achilleas N Pitsillides; Honghuang Lin; Narayanan Veeraraghavan; Jennifer A Brody; Ginger A Metcalf; Donna M Muzny; Richard A Gibbs; Diane M Becker; Lewis C Becker; Nauder Faraday; Rasika A Mathias; Lisa R Yanek; Eric Boerwinkle; L Adrienne Cupples; Andrew D Johnson Journal: Thromb Haemost Date: 2017-03-16 Impact factor: 5.249
Authors: Rehan Qayyum; Lewis C Becker; Diane M Becker; Nauder Faraday; Lisa R Yanek; Suzanne M Leal; Chad Shaw; Rasika Mathias; Bhoom Suktitipat; Paul F Bray Journal: BMC Genet Date: 2015-05-30 Impact factor: 2.797
Authors: Kai Kammers; Margaret A Taub; Ingo Ruczinski; Joshua Martin; Lisa R Yanek; Alyssa Frazee; Yongxing Gao; Dixie Hoyle; Nauder Faraday; Diane M Becker; Linzhao Cheng; Zack Z Wang; Jeff T Leek; Lewis C Becker; Rasika A Mathias Journal: PLoS One Date: 2017-01-20 Impact factor: 3.240
Authors: Mariana Muñoz-Esquerre; José Luis Ferreiro; Daniel Huertas; Ana Lucrecia Marcano; Marta López-Sánchez; Gerard Roura; Joan Antoni Gómez-Hospital; Jordi Dorca; Angel Cequier; Salud Santos Journal: Int J Chron Obstruct Pulmon Dis Date: 2017-12-28